Literature DB >> 12000754

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.

Elicia Penuel1, Robert W Akita, Mark X Sliwkowski.   

Abstract

Ligand-independent ErbB2 activation occurs principally by two distinct mechanisms: overexpression and mutation. Overexpression of ErbB2 at the plasma membrane drives receptor self-association in a concentration-dependent manner, which in turn leads to constitutive receptor activation. Subsets of human breast cancers contain a molecular alteration that leads to erbB2 gene amplification and subsequent protein overexpression. Although not recognized to occur in human cancers, mutation can also lead to increased ErbB2 association. A well characterized mutant of the rodent ortholog neu involves substitution of glutamate for valine within the transmembrane domain. In each case, a number of explanations have been proposed to explain the resulting ErbB2 activation. These include stabilization of receptor oligomers, release of negative constraints, and altered receptor conformations. Here we define a short amino acid segment comprising amino acids 966-968 in the intracellular domain that seemingly disrupts receptor-receptor association that is driven either by overexpression or mutation in the transmembrane region. Because of the hydrophobic nature of these amino acids (VVI), we propose that alteration of this segment likely results in a global conformational change in an area that has been proposed previously to be a dimerization motif for ErbB homomeric association.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000754     DOI: 10.1074/jbc.M202510200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis.

Authors:  Peter Nagy; Jeroen Claus; Thomas M Jovin; Donna J Arndt-Jovin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-02       Impact factor: 11.205

2.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

Review 3.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

4.  PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Authors:  Howard M Stern; Humphrey Gardner; Tomasz Burzykowski; Wafaa Elatre; Carol O'Brien; Mark R Lackner; Gary A Pestano; Angela Santiago; Ivonne Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Paolo Nuciforo; Valerie Bee; John Mackey; Dennis J Slamon; Michael F Press
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

5.  ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.

Authors:  Gabriele D'Uva; Alla Aharonov; Mattia Lauriola; David Kain; Yfat Yahalom-Ronen; Silvia Carvalho; Karen Weisinger; Elad Bassat; Dana Rajchman; Oren Yifa; Marina Lysenko; Tal Konfino; Julius Hegesh; Ori Brenner; Michal Neeman; Yosef Yarden; Jonathan Leor; Rachel Sarig; Richard P Harvey; Eldad Tzahor
Journal:  Nat Cell Biol       Date:  2015-04-06       Impact factor: 28.824

6.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

Review 7.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

8.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

9.  Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.

Authors:  Ian Todd; Paul M Radford; Kelly-Ann Draper-Morgan; Richard McIntosh; Susan Bainbridge; Peter Dickinson; Lama Jamhawi; Marios Sansaridis; Mary L Huggins; Patrick J Tighe; Richard J Powell
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

10.  ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.

Authors:  Diego Alvarado; Daryl E Klein; Mark A Lemmon
Journal:  Nature       Date:  2009-08-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.